Physician profile
Benjamin I Blank
NPI 1891786455
$9,320.45
in general payments reported to CMS, 2019-2025
45 companies · $783 in 2025
The $783 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,575 · 2020: $1,612 · 2021: $1,614 · 2022: $1,688 · 2023: $1,138 · 2024: $911 · 2025: $783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,832.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,832.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,071.76 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $1,015.00 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $692.85 | 2019-2025 | Otezla, Repatha, Evenity |
| Abbvie INC. | $665.66 | 2019-2025 | Qulipta, Ubrelvy |
| Novo Nordisk INC | $554.46 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $547.02 | 2019-2024 | |
| Lilly USA, LLC | $396.72 | 2019-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $338.20 | 2019-2024 | Verquvo, Steglatro, Segluromet |
| Boehringer Ingelheim Pharmaceuticals, INC. | $336.61 | 2019-2023 | Synjardy, Jardiance, Tradjenta |
| Abbott Laboratories | $326.32 | 2021-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $314.51 | 2019-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $216.05 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $207.60 | 2019-2023 | |
| Amarin Pharma, INC. | $192.89 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $126.52 | 2020-2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Blank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.